TripleBlind Announces Partnership with SEQSTER to Accelerate Data-Driven Patient Outcomes
Pharmaceutical companies and healthcare organizations will now have access to plug-and-play compatibility for clinical trials and beyond
TripleBlind, the leader in privacy-enhancing computation (PEC),announced a technology and go-to-market partnership with SEQSTER PDM (“SEQSTER”), the leader in patient-centric healthcare data technology, to develop a privacy preserving end-to-end data solution. This new partnership will enable healthcare organizations and pharmaceutical companies to gain important insights from data and improve patient outcomes.
Recommended AI News: AB Tasty and Mixpanel Announce Two New Integrations to Accelerate Digital Product Innovation
“SEQSTER has solved one of the biggest problems in healthcare: patient real-time access to health data, so why shouldn’t we do the same for healthcare organizations?” said Riddhiman Das, Co-founder and CEO of TripleBlind. “Together, TripleBlind and SEQSTER are now able to provide researchers and data scientists with access to incredibly valuable data that will spur innovation in the healthcare industry and, ultimately, save lives.”
Historically, healthcare data has been siloed and things like clinical trials have required manual data entry. As the healthcare industry continues to move towards digital transformation, health organizations increasingly need the ability to aggregate multiple, disparate data sources in real time to gain actionable insights for research and development. TripleBlind and SEQSTER’s privacy preserving end-to-end data platform reduces the costs associated with digital evolution in the healthcare industry, while more effectively and efficiently protecting the privacy of data.
SEQSTER automates that process and combines the data in one operating system that allows pharmaceutical researchers the ability to run studies that are more effective and efficient. With TripleBlind, the data is quickly and easily analyzed, resulting in actionable yet anonymized data that can impact everything from identifying off-label use cases to better patient interactions to improved processing of claims and beyond. This is all done with full regulatory compliance, including HIPAA.
Recommended AI News: Darktrace Adds Early Warning System to Antigena Email
“TripleBlind is the only company that is able to maintain the level of privacy needed to be HIPAA and GDPR compliant, while providing the ability to learn from data and this is exactly what our customers have been looking for,” said Ardy Arianpour, CEO of SEQSTER.
“We’ve tackled the biggest issues in healthcare – data accessibility and data interoperability – yet there’s still a major opportunity to more efficiently use data from clinical trials to improve patient reported outcomes. To say that I’m excited about our new partnership with TripleBlind is an understatement – the combination of these two technologies will be impactful for researchers, patients, and Pharma enterprises at scale.”
[To share your insights with us, please write to firstname.lastname@example.org]